You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFelbamate
Accession NumberDB00949  (APRD00505)
TypeSmall Molecule
GroupsApproved
DescriptionFelbamate is an anticonvulsant drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
Structure
Thumb
Synonyms
2-Phenyl-1,3-propanediol dicarbamate
Carbamic acid 2-phenyltrimethylene ester
Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester
Felbamate
Felbamato
Felbamatum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Felbamatetablet600 mg/1oralWallace Pharmaceuticals Inc.2011-11-11Not applicableUs
Felbamatesuspension600 mg/5mLoralWallace Pharmaceuticals Inc.2011-11-23Not applicableUs
Felbamatetablet400 mg/1oralWallace Pharmaceuticals Inc.2011-11-11Not applicableUs
Felbatoltablet400 mg/1oralMeda Pharmaceuticals Inc.1993-07-29Not applicableUs
Felbatoltablet600 mg/1oralMeda Pharmaceuticals Inc.1993-07-29Not applicableUs
Felbatolsuspension600 mg/5mLoralMeda Pharmaceuticals Inc.1993-07-29Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Felbamatetablet600 mg/1oralMylan Pharmaceuticals Inc.2016-01-12Not applicableUs
Felbamatetablet400 mg/1oralMarlex Pharmaceuticals Inc2015-08-01Not applicableUs
Felbamatetablet600 mg/1oralAmneal Pharmaceuticals of New York, LLC2011-09-16Not applicableUs
Felbamatetablet600 mg/1oralMarlex Pharmaceuticals Inc2015-08-01Not applicableUs
Felbamatetablet600 mg/1oralCarilion Materials Management2011-09-16Not applicableUs
Felbamatesuspension600 mg/5mLoralAmneal Pharmaceuticals of New York, LLC2011-12-16Not applicableUs
Felbamatetablet400 mg/1oralMylan Pharmaceuticals Inc.2016-01-12Not applicableUs
Felbamatetablet400 mg/1oralAmneal Pharmaceuticals of New York, LLC2011-09-16Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FelbamylNot Available
TaloxaNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIX72RBB02N8
CAS number25451-15-4
WeightAverage: 238.2399
Monoisotopic: 238.095356946
Chemical FormulaC11H14N2O4
InChI KeyInChIKey=WKGXYQFOCVYPAC-UHFFFAOYSA-N
InChI
InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
IUPAC Name
3-(carbamoyloxy)-2-phenylpropyl carbamate
SMILES
NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassNot Available
Direct ParentBenzene and substituted derivatives
Alternative Parents
Substituents
  • Monocyclic benzene moiety
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
PharmacodynamicsFelbamate is an antiepileptic indicated as monotherapy or as an adjunct to other anticonvulsants for the treatment of partial seizures resulting from epilepsy. Receptor-binding studies in vitro indicate that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex. However, felbamate does interact as an antagonist at the strychnine-insensitive glycine recognition site of the NMDA receptor-ionophore complex.
Mechanism of actionThe mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. In vitro receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. It is also indicated that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding.
Related Articles
Absorption>90%
Volume of distribution
  • 756±82 mL/kg
Protein binding20-36%
Metabolism

Hepatic

SubstrateEnzymesProduct
Felbamate
2-Phenyl-1,3-propanediol monocarbamateDetails
Felbamate
p-HydroxyfelbamateDetails
Felbamate
2-HydroxyfelbamateDetails
2-Phenyl-1,3-propanediol monocarbamate
3-Carbamoyl-2-phenylpropionaldehydeDetails
3-Carbamoyl-2-phenylpropionaldehyde
Not Available
AtropaldehydeDetails
3-Carbamoyl-2-phenylpropionaldehyde
Not Available
4-Hydroxy-5-phenyltetrahydro-1,3-oxazin-2-oneDetails
3-Carbamoyl-2-phenylpropionaldehyde
3-Carbamoyl-2-phenylpropionic acidDetails
4-Hydroxy-5-phenyltetrahydro-1,3-oxazin-2-one
5-Phenyl-1,3-oxazinane-2,4-dioneDetails
5-Phenyl-1,3-oxazinane-2,4-dione
Not Available
3-Carbamoyl-2-phenylpropionic acidDetails
Route of eliminationNot Available
Half life20-23 hours
Clearance
  • 26 +/- 3 mL/hr/kg [single 1200 mg dose]
  • 30 +/- 8 mL/hr/kg [multiple daily doses of 3600 mg]
ToxicityLD50=5000 mg/kg (Orally in rats)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Felbamate Metabolism PathwayDrug metabolismSMP00633
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9544
Blood Brain Barrier+0.9805
Caco-2 permeable-0.6324
P-glycoprotein substrateNon-substrate0.783
P-glycoprotein inhibitor INon-inhibitor0.9551
P-glycoprotein inhibitor IINon-inhibitor0.932
Renal organic cation transporterNon-inhibitor0.9039
CYP450 2C9 substrateNon-substrate0.9009
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7942
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9184
CYP450 2D6 inhibitorInhibitor0.7126
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9271
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.8338
BiodegradationNot ready biodegradable0.8068
Rat acute toxicity1.7095 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9872
hERG inhibition (predictor II)Non-inhibitor0.9786
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Meda pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Suspensionoral600 mg/5mL
Tabletoral400 mg/1
Tabletoral600 mg/1
Prices
Unit descriptionCostUnit
Felbatol 600 mg tablet3.1USD tablet
Felbatol 400 mg tablet2.71USD tablet
Felbatol 600 mg/5ml Suspension1.43USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4978680 No1992-09-262009-09-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point151.5 °CPhysProp
water solubilitySlightly soluble in waterNot Available
logP0.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.742 mg/mLALOGPS
logP0.56ALOGPS
logP0.68ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)14.98ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area104.64 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity59.59 m3·mol-1ChemAxon
Polarizability23.52 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0udi-5900000000-673caaab3dded596924cView in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Jacobs MP, Bertram E, Cereghino JJ, et al.: Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 1991 Nov;41(11):1785-9. [PubMed:1944909 ]
External Links
ATC CodesN03AX10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (47.1 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Felbamate.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Felbamate.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Felbamate.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Felbamate.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Felbamate.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Felbamate.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Felbamate.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Felbamate.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Felbamate.
AmiodaroneThe metabolism of Felbamate can be decreased when combined with Amiodarone.
AmiodaroneFelbamate may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Felbamate.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Felbamate.
AmobarbitalThe serum concentration of Amobarbital can be increased when it is combined with Felbamate.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Felbamate.
AmoxapineThe risk or severity of adverse effects can be increased when Felbamate is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Felbamate.
AnagrelideFelbamate may increase the QTc-prolonging activities of Anagrelide.
AprepitantThe serum concentration of Felbamate can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Felbamate.
Arsenic trioxideFelbamate may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherFelbamate may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Felbamate.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Felbamate.
AtazanavirThe metabolism of Felbamate can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Felbamate can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Felbamate.
AzelastineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Felbamate.
AzithromycinFelbamate may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Felbamate.
BarbitalThe serum concentration of Barbital can be increased when it is combined with Felbamate.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Felbamate.
BedaquilineFelbamate may increase the QTc-prolonging activities of Bedaquiline.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Felbamate.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Felbamate.
BexaroteneThe serum concentration of Felbamate can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Felbamate can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Felbamate can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Felbamate can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Felbamate is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
BrimonidineThe risk or severity of adverse effects can be increased when Felbamate is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Felbamate.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Felbamate.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Felbamate.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Felbamate.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Felbamate.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Felbamate.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Felbamate.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Felbamate.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Felbamate.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Felbamate.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Felbamate.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Felbamate.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Felbamate.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Felbamate.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Felbamate.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Felbamate.
CeritinibThe serum concentration of Felbamate can be increased when it is combined with Ceritinib.
CeritinibFelbamate may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Felbamate.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Felbamate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Felbamate.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Felbamate.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Felbamate.
ChloroquineFelbamate may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Felbamate is combined with Chlorphenamine.
ChlorpromazineFelbamate may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Felbamate.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Felbamate.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Felbamate.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Felbamate.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Felbamate.
CiprofloxacinFelbamate may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideFelbamate may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Felbamate is combined with Citalopram.
ClarithromycinFelbamate may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Felbamate can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Felbamate can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Felbamate is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Felbamate.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Felbamate.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Felbamate.
ClomipramineThe risk or severity of adverse effects can be increased when Felbamate is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Felbamate is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Felbamate.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Felbamate.
ClotrimazoleThe metabolism of Felbamate can be decreased when combined with Clotrimazole.
ClozapineFelbamate may increase the QTc-prolonging activities of Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Felbamate.
CobicistatThe metabolism of Felbamate can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Felbamate.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Felbamate.
ConivaptanThe serum concentration of Felbamate can be increased when it is combined with Conivaptan.
CrizotinibFelbamate may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Felbamate can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Felbamate is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Felbamate.
CyclosporineThe metabolism of Felbamate can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Felbamate.
Cyproterone acetateThe serum concentration of Felbamate can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Felbamate can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Felbamate is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Felbamate.
DapoxetineThe risk or severity of adverse effects can be increased when Felbamate is combined with Dapoxetine.
DarunavirThe metabolism of Felbamate can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Felbamate can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Felbamate can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Felbamate can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Felbamate.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Felbamate.
DesipramineThe risk or severity of adverse effects can be increased when Felbamate is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Felbamate is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Felbamate.
DexamethasoneThe serum concentration of Felbamate can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Felbamate.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felbamate.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Felbamate.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Felbamate.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Felbamate.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Felbamate.
DifenoxinThe risk or severity of adverse effects can be increased when Felbamate is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Felbamate.
DihydroergotamineThe metabolism of Felbamate can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Felbamate.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Felbamate.
DiltiazemThe metabolism of Felbamate can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Felbamate is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Felbamate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Felbamate.
DisopyramideFelbamate may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Felbamate can be decreased when combined with Disulfiram.
DofetilideFelbamate may increase the QTc-prolonging activities of Dofetilide.
DolasetronFelbamate may increase the QTc-prolonging activities of Dolasetron.
DomperidoneFelbamate may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Felbamate.
DoxepinThe risk or severity of adverse effects can be increased when Felbamate is combined with Doxepin.
DoxycyclineThe metabolism of Felbamate can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
DoxylamineThe risk or severity of adverse effects can be increased when Felbamate is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Felbamate.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
DronedaroneThe metabolism of Felbamate can be decreased when combined with Dronedarone.
DronedaroneFelbamate may increase the QTc-prolonging activities of Dronedarone.
DroperidolFelbamate may increase the QTc-prolonging activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Felbamate.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Felbamate.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Felbamate.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Felbamate.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Felbamate.
EfavirenzThe serum concentration of Felbamate can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Felbamate is combined with Efavirenz.
EliglustatFelbamate may increase the QTc-prolonging activities of Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Felbamate.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Felbamate.
EnzalutamideThe serum concentration of Felbamate can be decreased when it is combined with Enzalutamide.
ErythromycinFelbamate may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Felbamate can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Felbamate is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Felbamate can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Felbamate.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Felbamate.
EthanolFelbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Felbamate.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Felbamate.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Felbamate.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Felbamate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Felbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Felbamate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Felbamate.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Felbamate.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Felbamate.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Felbamate.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Felbamate.
EtoperidoneThe risk or severity of adverse effects can be increased when Felbamate is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Felbamate.
EtravirineThe serum concentration of Felbamate can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Felbamate is combined with Ezogabine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Felbamate.
FenfluramineThe risk or severity of adverse effects can be increased when Felbamate is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Felbamate.
FexofenadineThe risk or severity of adverse effects can be increased when Felbamate is combined with Fexofenadine.
FlecainideFelbamate may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Felbamate is combined with Flibanserin.
FluconazoleThe metabolism of Felbamate can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Felbamate.
FlunarizineThe risk or severity of adverse effects can be increased when Felbamate is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Felbamate.
FluoxetineThe risk or severity of adverse effects can be increased when Felbamate is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Felbamate.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Felbamate.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Felbamate.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Felbamate.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Felbamate.
FluvoxamineThe risk or severity of adverse effects can be increased when Felbamate is combined with Fluvoxamine.
FluvoxamineThe metabolism of Felbamate can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Felbamate can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Felbamate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Felbamate is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Felbamate.
Fusidic AcidThe serum concentration of Felbamate can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Felbamate.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Felbamate is combined with gabapentin enacarbil.
Gadobenic acidFelbamate may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Felbamate.
GemifloxacinFelbamate may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Felbamate.
GoserelinFelbamate may increase the QTc-prolonging activities of Goserelin.
GranisetronFelbamate may increase the QTc-prolonging activities of Granisetron.
GuanfacineThe risk or severity of adverse effects can be increased when Felbamate is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Felbamate.
HaloperidolFelbamate may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Felbamate.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Felbamate.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Felbamate.
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Felbamate.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Felbamate.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Felbamate.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Felbamate.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Felbamate.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
HydroxyzineThe risk or severity of adverse effects can be increased when Felbamate is combined with Hydroxyzine.
IbutilideFelbamate may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Felbamate can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Felbamate is combined with Iloperidone.
ImatinibThe metabolism of Felbamate can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Felbamate.
IndalpineThe risk or severity of adverse effects can be increased when Felbamate is combined with Indalpine.
IndinavirThe metabolism of Felbamate can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Felbamate can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Felbamate.
IsoniazidThe metabolism of Felbamate can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Felbamate can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Felbamate can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Felbamate can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Felbamate.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Felbamate.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Felbamate.
KetoconazoleThe metabolism of Felbamate can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Felbamate.
LenvatinibFelbamate may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideFelbamate may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Felbamate is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Felbamate.
LevocabastineThe risk or severity of adverse effects can be increased when Felbamate is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Felbamate is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Felbamate is combined with Levodopa.
LevofloxacinFelbamate may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Felbamate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Felbamate is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Felbamate.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Felbamate.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Felbamate.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Felbamate.
LopinavirThe metabolism of Felbamate can be decreased when combined with Lopinavir.
LopinavirFelbamate may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Felbamate.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Felbamate.
LovastatinThe metabolism of Felbamate can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Felbamate.
Lu AA21004The risk or severity of adverse effects can be increased when Felbamate is combined with Lu AA21004.
LuliconazoleThe serum concentration of Felbamate can be increased when it is combined with Luliconazole.
LumefantrineFelbamate may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Felbamate.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Felbamate is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Felbamate.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Felbamate.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Felbamate.
MefloquineThe therapeutic efficacy of Felbamate can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Felbamate.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Felbamate.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Felbamate.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Felbamate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Felbamate.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Felbamate.
MethadoneFelbamate may increase the QTc-prolonging activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Felbamate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Felbamate.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Felbamate.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Felbamate.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Felbamate.
MethohexitalThe serum concentration of Methohexital can be increased when it is combined with Felbamate.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Felbamate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Felbamate.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Felbamate.
MethsuximideThe risk or severity of adverse effects can be increased when Felbamate is combined with Methsuximide.
MethylphenobarbitalThe serum concentration of Methylphenobarbital can be increased when it is combined with Felbamate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Felbamate.
MetyrosineFelbamate may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Felbamate can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Felbamate.
MifepristoneThe metabolism of Felbamate can be decreased when combined with Mifepristone.
MifepristoneFelbamate may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Felbamate is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
MirtazapineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Felbamate.
MitotaneThe serum concentration of Felbamate can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Felbamate can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Felbamate.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Felbamate.
MoxifloxacinFelbamate may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
NabiloneThe risk or severity of adverse effects can be increased when Felbamate is combined with Nabilone.
NafcillinThe serum concentration of Felbamate can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Felbamate.
NefazodoneThe metabolism of Felbamate can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Felbamate can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Felbamate can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Felbamate can be decreased when combined with Nevirapine.
NicotineThe metabolism of Felbamate can be decreased when combined with Nicotine.
NilotinibThe metabolism of Felbamate can be decreased when combined with Nilotinib.
NilotinibFelbamate may increase the QTc-prolonging activities of Nilotinib.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Felbamate.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Felbamate.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Felbamate.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Felbamate.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Felbamate.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Felbamate.
OfloxacinFelbamate may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Felbamate is combined with Olanzapine.
OlaparibThe metabolism of Felbamate can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Felbamate.
OndansetronFelbamate may increase the QTc-prolonging activities of Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Felbamate.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Felbamate.
OrlistatThe serum concentration of Felbamate can be decreased when it is combined with Orlistat.
OrphenadrineFelbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Felbamate.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Felbamate.
OsimertinibThe serum concentration of Felbamate can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Felbamate.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Felbamate.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Felbamate.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Felbamate.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Felbamate.
PalbociclibThe serum concentration of Felbamate can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Felbamate.
PanobinostatFelbamate may increase the QTc-prolonging activities of Panobinostat.
ParaldehydeFelbamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Felbamate.
ParoxetineThe risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine.
PazopanibFelbamate may increase the QTc-prolonging activities of Pazopanib.
PentamidineFelbamate may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Felbamate.
PentobarbitalThe serum concentration of Pentobarbital can be increased when it is combined with Felbamate.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Felbamate.
PerampanelThe risk or severity of adverse effects can be increased when Felbamate is combined with Perampanel.
PerflutrenFelbamate may increase the QTc-prolonging activities of Perflutren.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Felbamate.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Felbamate.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Felbamate.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Felbamate.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Felbamate.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Felbamate.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Felbamate.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Felbamate.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Felbamate.
PipotiazineThe risk or severity of adverse effects can be increased when Felbamate is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Felbamate is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Felbamate is combined with Pomalidomide.
PosaconazoleThe metabolism of Felbamate can be decreased when combined with Posaconazole.
PramipexoleFelbamate may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Felbamate.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Felbamate.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Felbamate.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Felbamate.
PrimaquineFelbamate may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Primidone can be increased when it is combined with Felbamate.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Felbamate.
ProcainamideFelbamate may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Felbamate.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Felbamate.
PromazineFelbamate may increase the QTc-prolonging activities of Promazine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Felbamate.
PromethazineThe risk or severity of adverse effects can be increased when Felbamate is combined with Promethazine.
PropafenoneFelbamate may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Felbamate.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Felbamate.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Felbamate.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Felbamate.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Felbamate.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Felbamate.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Felbamate.
QuinidineFelbamate may increase the QTc-prolonging activities of Quinidine.
QuinineFelbamate may increase the QTc-prolonging activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Felbamate is combined with Ramelteon.
RanolazineThe metabolism of Felbamate can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Felbamate.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Felbamate.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Felbamate.
RifabutinThe metabolism of Felbamate can be increased when combined with Rifabutin.
RifampicinThe metabolism of Felbamate can be increased when combined with Rifampicin.
RifapentineThe metabolism of Felbamate can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Felbamate.
RitonavirThe metabolism of Felbamate can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Felbamate.
RopiniroleFelbamate may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Felbamate.
RotigotineFelbamate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Felbamate.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Felbamate.
SaquinavirFelbamate may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Felbamate can be decreased when combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Felbamate.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Felbamate.
SecobarbitalThe serum concentration of Secobarbital can be increased when it is combined with Felbamate.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Felbamate.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Felbamate.
SertralineThe risk or severity of adverse effects can be increased when Felbamate is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Felbamate.
SildenafilThe metabolism of Felbamate can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Felbamate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Felbamate can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Felbamate.
SotalolFelbamate may increase the QTc-prolonging activities of Sotalol.
St. John's WortThe serum concentration of Felbamate can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Felbamate is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Felbamate.
SulfisoxazoleFelbamate may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Felbamate can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Felbamate.
SuvorexantThe risk or severity of adverse effects can be increased when Felbamate is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Felbamate is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Felbamate is combined with Tasimelteon.
TelaprevirThe metabolism of Felbamate can be decreased when combined with Telaprevir.
TelavancinFelbamate may increase the QTc-prolonging activities of Telavancin.
TelithromycinFelbamate may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Felbamate can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Felbamate.
TetrabenazineThe risk or severity of adverse effects can be increased when Felbamate is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Felbamate.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Felbamate.
ThalidomideFelbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Felbamate.
ThiamylalThe serum concentration of Thiamylal can be increased when it is combined with Felbamate.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Felbamate.
ThiopentalThe serum concentration of Thiopental can be increased when it is combined with Felbamate.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Felbamate.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Felbamate.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Felbamate.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Felbamate.
TiclopidineThe metabolism of Felbamate can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Felbamate.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Felbamate.
TocilizumabThe serum concentration of Felbamate can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Felbamate.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Felbamate.
ToremifeneFelbamate may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Felbamate.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Felbamate.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Felbamate.
TrazodoneThe risk or severity of adverse effects can be increased when Felbamate is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Felbamate.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Felbamate.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Felbamate.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Felbamate.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Felbamate.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Felbamate.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Felbamate.
VandetanibFelbamate may increase the QTc-prolonging activities of Vandetanib.
VemurafenibFelbamate may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Felbamate can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Felbamate can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Felbamate is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Felbamate is combined with Vilazodone.
VoriconazoleThe metabolism of Felbamate can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Felbamate is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Felbamate.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Felbamate.
ZiconotideThe risk or severity of adverse effects can be increased when Felbamate is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Felbamate is combined with Zimelidine.
ZiprasidoneThe metabolism of Felbamate can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Felbamate is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Felbamate.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Felbamate.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Felbamate.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Felbamate.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Felbamate.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Felbamate.
Food Interactions
  • Taking it after a meal may reduce the incidence of adverse effects.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an ...
Gene Name:
GRIN2B
Uniprot ID:
Q13224
Molecular Weight:
166365.885 Da
References
  1. Kleckner NW, Glazewski JC, Chen CC, Moscrip TD: Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. J Pharmacol Exp Ther. 1999 May;289(2):886-94. [PubMed:10215667 ]
  2. Harty TP, Rogawski MA: Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 2000 Mar;39(1):47-55. [PubMed:10690753 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Chang HR, Kuo CC: Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45. doi: 10.1021/jm0706618. Epub 2008 Feb 27. [PubMed:18311896 ]
  5. Luszczki JJ, Danysz W, Czuczwar SJ: Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2008;81(3):259-65. doi: 10.1159/000114870. Epub 2008 Feb 4. [PubMed:18253065 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits.
Gene Name:
GRIN2A
Uniprot ID:
Q12879
Molecular Weight:
165281.215 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Foye, William O.;Williams, David A.;Lemke, Thomas L. (2002). Foye's Principles of Medicinal Chemistry (5th ed.). Lippincott Williams & Wilkins. [ISBN:0683307371 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23